A1070722

Manufactured by Bio-Techne

Sourced in United Kingdom

The A1070722 is a laboratory equipment product manufactured by Bio-Techne. It is designed to perform a specific core function within the laboratory setting. However, a detailed description of the product's features and capabilities cannot be provided in an unbiased and factual manner without the risk of extrapolation or interpretation. As a result, the description for this product is not available.

Automatically generated - may contain errors

Lab products found in correlation

Lithium chloride (licl), by Merck Group (1 mentions) Krc0061, by Thermo Fisher Scientific (1 mentions) Mdl28170, by Bio-Techne (1 mentions) Sb415286, by Merck Group (1 mentions) Nfκb inhibitor bay 11 7085, by Merck Group (1 mentions) Pi3k inhibitor ly294002, by Cell Signaling Technology (1 mentions)

2 protocols using a1070722

Inhibition of Calpain and GSK-3 in DRGN

Check if the same lab product or an alternative is used in the 5 most similar protocols

DRGN were maintained in 96-well plates at 12,000 cells/well and treated with 100 nM PTX for 24 h and co-incubated with the calpain inhibitor MDL28170 (1 µM; Tocris Bioscience, Bristol, UK), Lithium chloride (0.5 and 1 mM; Sigma Aldrich, St Louis, MO, USA), the glycogen synthase kinase-3 (GSK-3) inhibitor A1070722 (50 nM; Tocris Bioscience, Bristol, UK) or their corresponding vehicle. After 24 h, supernatant was collected and snap frozen in liquid nitrogen. IL-6 concentrations were determined by enzyme-linked immunosorbent assay (ELISA; KRC0061, LifeTechnologies, Darmstadt, Germany) following the manufacturer’s protocol. All samples were measured as doublets (technical replicates). An appropriate standard curve ranging from 0 to 1500 pg/ml was carried according to the manufacturer’s instructions.

Huehnchen P., Muenzfeld H., Boehmerle W, & Endres M. (2020). Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice. Cell Death & Disease, 11(1), 45.

+ Open protocol

+ Expand

Modulation of RA FLS Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

RA FLS were serum starved in DMEM containing 0.1% FBS. FLS were then were preincubated with either 0.5 μM NFκB inhibitor Bay 11-7085 (Sigma-Aldrich) or 1 μM PI3K inhibitor LY294002 (Cell Signaling Technology) for 1 hour before stimulation with TNFα (5 ng/ml) for 12 hours. For inhibition of GSK3β, serum starved RA FLS were treated with either 20 μM GSK3β inhibitor SB 415286 (iGSK3β_1; Sigma-Aldrich) or 20 nM GSK3β inhibitor A1070722 (iGSK3β_2; Tocris Bioscience) for 12 hours.

Svensson M.N., Zoccheddu M., Yang S., Nygaard G., Secchi C., Doody K.M., Slowikowski K., Mizoguchi F., Humby F., Hands R., Santelli E., Sacchetti C., Wakabayashi K., Wu D.J., Barback C., Ai R., Wang W., Sims G.P., Mydel P., Kasama T., Boyle D.L., Galimi F., Vera D., Tremblay M.L., Raychaudhuri S., Brenner M.B., Firestein G.S., Pitzalis C., Ekwall A.K., Stanford S.M, & Bottini N. (2020). Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Science Advances, 6(26), eaba4353.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!